This CME activity is supported by an educational grant from Quest Diagnostics, Madison,
New Jersey.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).Circulation. 2002; 106: 3143-3421
- New risk factors for atherosclerosis and patient risk assessment.Circulation. 2004; 109: III15
- Lipoprotein physiology.Endocrinol Metab Clin North Am. 1998; 27: 503-519
- ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.J Intern Med. 2006; 259: 247-258
- The rationale for using apoA-1 as a clinical markers of cardiovascular risk.J Intern Med. 2006; 259: 447-454
- The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence.J Intern Med. 2006; 259: 493-519
- Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?.Am J Cardiol. 2006; 97: 943-946
- Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.JAMA. 2007; 298: 776-785
- Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.JAMA. 2005; 294: 326-333
- Role of apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.Ann Intern Med. 2007; 146: 640-648
- Atherogenic, dense low-density lipoproteins.Eur Heart J. 1998; 19: A24-A30
- Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.Arterioscler Thromb Vasc Biol. 1991; 11: 298-306
- Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size.Atherosclerosis. 1999; 93: 189-199
- Antiatherogenic small, dense HDL—guardian angel of the arterial wall?.Nat Clin Pract Cardiovasc Med. 2006; 3: 144-153
- Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.JAMA. 2007; 298: 299-308
- Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.JAMA. 2007; 298: 309-316
- Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.J Cardiovasc Risk. 1996; 3: 213-219
- Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region.Circulation. 2004; 110: 2678-2686
- Effect of recombinant ApoA-1 Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.JAMA. 2003; 290: 2292-2300
- Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-1 Milano.J Am Coll Cardiol. 2006; 47: 992-997
- Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.N Engl J Med. 2001; 345: 1583-1592
- Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A1.Nature. 1991; 353: 265-267
- Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.JAMA. 1990; 264: 3007-3012
- Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-1 ratio to identify the lipoprotein-related risk of vascular disease.J Intern Med. 2006; 259: 455-461
- Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.N Engl J Med. 1990; 323: 1289-1298
- Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a).JAMA. 1995; 274: 1771-1774
- Estrogen and progestin, Lp(a) and the risk of recurrent coronary heart disease events after menopause.JAMA. 2000; 283: 1845-1852
- Relation of age, the apolipoprotein b/apolipoprotein a-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease.Am J Cardiol. 2007; 100: 217-221
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.Lancet. 2004; 364: 937-952
- Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease.Circulation. 2001; 104: 2295-2299
- Alcohol consumption and lipoprotein subclasses in older adults.J Clin Endocrinol Metab. 2007; 92: 2559-2566
Article Info
Publication History
Accepted:
December 13,
2007
Received in revised form:
December 13,
2007
Received:
December 12,
2007
Footnotes
This discussion took place at Baylor University Medical Center, Dallas, Texas, on June 19, 2007.
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
